Viking Therapeutics reported Feb. 27 strong results from a phase 2 trial of a new drug that could rival other GLP-1 anti-obesity medications like Ozempic, Mounjaro and Wegovy.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
